Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Chemomab Therapeutics Ltd DRC (CMMB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Chemomab Therapeutics DRC's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.6599 -0.0201    -2.96%
22/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.6488
-0.0111
-1.6821%
19:01:50 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 9,520
  • Bid/Ask: 0.6203 / 0.7013
  • Day's Range: 0.6219 - 0.6650
Chemomab Therapeutics DRC 0.6599 -0.0201 -2.96%

CMMB Recent Sentiments

 
This page contains information on users’ sentiments for the Chemomab Therapeutics Ltd DRC stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Apr 18, 2024 LORENZO TILLI   0.6500 +1.52%
Apr 16, 2024 cosmin serbanescu   0.7000 -5.73%
Mar 06, 2024 LORENZO TILLI   0.7200 Mar 29, 2024 @ 0.7800 +8.33%
Feb 20, 2024 Andreas Schatz   0.6800 Mar 15, 2024 @ 0.8000 +17.65%
Feb 09, 2024 Omar Falletti   0.5900 Mar 01, 2024 @ 0.6600 +11.86%
Jan 30, 2024 LORENZO TILLI   0.5800 Feb 23, 2024 @ 0.7200 +24.14%
Dec 06, 2023 Сергей Ляхов   0.5000 Dec 29, 2023 @ 0.5100 +2.00%
Dec 04, 2023 Amin Homaei   0.5200 Dec 04, 2023 @ 0.5300 -1.92%
Nov 17, 2023 Amin Homaei   0.8000 Nov 30, 2023 @ 0.5600 -30.00%
Nov 15, 2023 Tony Lips   0.8100 Nov 28, 2023 @ 0.5400 -33.33%
Nov 15, 2023 Darren Blom   1.1000 Nov 30, 2023 @ 0.5600 -49.09%
Sep 28, 2023 Marian cosmin...   0.9000 Nov 30, 2023 @ 0.5600 -37.78%
Sep 25, 2023 LORENZO TILLI   0.9300 Nov 30, 2023 @ 0.5600 -39.78%
Jun 26, 2023 Omar Falletti   1.2800 Nov 30, 2023 @ 0.5600 +56.25%
Jun 21, 2023 Eric Zambetti   1.5000 Nov 30, 2023 @ 0.5600 -62.67%
May 18, 2023 Muhammet Doğan   1.8300 Nov 30, 2023 @ 0.5600 +69.40%
May 11, 2023 Raffaella Pirola   1.6400 Nov 30, 2023 @ 0.5600 -65.85%
Apr 04, 2023 Raffaella Pirola   1.4600 May 09, 2023 @ 1.5400 +5.48%
Mar 01, 2023 Omar Falletti   1.8000 Mar 24, 2023 @ 1.6100 -10.56%
Feb 21, 2023 Raffaella Pirola   2.2900 Mar 17, 2023 @ 1.4700 -35.81%
Feb 21, 2023 youngsik cho   2.2900 Mar 17, 2023 @ 1.4700 -35.81%
Feb 21, 2023 Robbert Kuipers   2.4400 Mar 17, 2023 @ 1.4700 -39.75%
Feb 21, 2023 Robbert Kuipers   2.4400 Feb 21, 2023 @ 2.4400 0.00%
Jan 09, 2023 Muhammet Doğan   2.2200 Feb 03, 2023 @ 2.2200 0.00%
Jan 03, 2023 Cruzeiro dos Santos   3.4300 Jan 09, 2023 @ 2.2900 +33.24%
Jan 03, 2023 Soon Jang   3.7300 Jan 09, 2023 @ 2.2900 -38.61%
Dec 29, 2022 Robbert Kuipers   2.8900 Jan 20, 2023 @ 2.2600 -21.80%
Dec 29, 2022 Robbert Kuipers   2.8900 Dec 29, 2022 @ 2.8900 0.00%
Dec 29, 2022 Paolo Causarano   2.7600 Jan 20, 2023 @ 2.2600 -18.12%
Dec 29, 2022 Raffaella Pirola   2.7200 Jan 20, 2023 @ 2.2600 -16.91%
Dec 12, 2022 Halim Sunar   2.5800 Jan 06, 2023 @ 2.2600 -12.40%
Dec 12, 2022 Robbert Kuipers   2.9000 Jan 06, 2023 @ 2.2600 -22.07%
Dec 12, 2022 Robbert Kuipers   2.9000 Dec 12, 2022 @ 2.9000 0.00%
Nov 22, 2022 Roberto Larriba   1.9600 Nov 28, 2022 @ 2.0900 +6.63%
Sep 28, 2022 Daniel Andujar   2.5800 Oct 21, 2022 @ 2.0000 -22.48%
Sep 28, 2022 Raffaella Pirola   2.4700 Oct 21, 2022 @ 2.0000 -19.03%
Sep 23, 2022 Amy Binyamini   2.4900 Oct 14, 2022 @ 2.0000 -19.68%
Aug 17, 2022 ErezH   3.2600 Sep 09, 2022 @ 3.4600 +6.13%
Aug 17, 2022 ErezH   3.2600 Sep 09, 2022 @ 3.4600 +6.13%
Aug 03, 2022 Salih Kaya   3.1500 Aug 26, 2022 @ 3.3600 +6.67%
Jul 01, 2022 Salih Kaya   3.6000 Jul 22, 2022 @ 3.2400 -10.00%
Jun 07, 2022 Raffaella Pirola   4.0400 Jul 01, 2022 @ 3.3200 -17.82%
May 24, 2022 Salih Kaya   2.9000 Jun 17, 2022 @ 3.3200 +14.48%
Apr 28, 2022 أبو أمجد اليامي   3.1500 May 20, 2022 @ 3.0200 -4.13%
Apr 27, 2022 Salih Kaya   3.1200 May 20, 2022 @ 3.0200 -3.21%
Mar 24, 2022 Timo Saari   4.9900 Apr 21, 2022 @ 3.7400 +25.05%
Mar 01, 2022 Raffaella Pirola   4.5100 Mar 25, 2022 @ 4.9800 +10.42%
Feb 16, 2022 dfafoutis   4.4600 Mar 11, 2022 @ 4.2000 -5.83%
Jan 31, 2022 Mohammed Saleh   4.8800 Feb 25, 2022 @ 4.0400 +17.21%
Jan 20, 2022 Omar Falletti   5.6000 Feb 11, 2022 @ 4.3500 +22.32%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CMMB Comments

Write your thoughts about Chemomab Therapeutics Ltd DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Dimitris Fafoutis
dfafoutis Feb 16, 2022 11:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
7.8 first stop
matanel liberman
matanel liberman Oct 18, 2021 1:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
20 soon
Tiffa Lovina
Tiffa Lovina Mar 16, 2021 10:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what happened? why suddenly up?
Bryan Mishkin
Bryan Mishkin Mar 16, 2021 10:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Merger was approved by shareholders last night
Anthony Gautier
Anthony Gautier Dec 16, 2020 10:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The merger will create a company focused on advancing Chemomab’s lead product, CM-101, for the treatment of fibrosis-related diseases.
Anthony Gautier
Anthony Gautier Dec 15, 2020 4:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This should be a great marriage going forward
Micke Helenius
Micke Helenius Dec 15, 2020 4:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I wish.. any facts?
Anthony Gautier
Anthony Gautier Dec 15, 2020 4:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Facts are in the merger report that are in the news, that made my conclusion. Research on your own and state your conclusions. To each their own...It's you money invest wisely, make your own conclusions.
Tariq AlZadjali
Tariq AlZadjali Dec 15, 2020 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bo0om
Tyler Philipation
Tyler Philipation Jun 09, 2020 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i really dislike isreal stocks, from what ive seen they've never ended well for shareholders
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email